As such, don't trust it without independent verification.
Research is only the first step in the development of new therapeutic agents.
To convert scientific research into widely available products, companies must move from the research setting to commercial scale production. For production of the most complicated molecules, this step can often limit or delay the widespread availability of new products. Nowhere in pharmaceutical manufacturing has this proven more challenging than for the production of complex and sophisticated compounds created through the recombinant DNA techniques of genetic engineering. More akin to cultivation than traditional pharmaceutical production, the recombinant drug manufacturing process turns bacteria into tiny biological factories. To make commercial quantities of a recombinant DNA product recombinant E. coli are modified by inserting the gene needed for production of the desired protein.